CN1348375A - 用于促进神经细胞分化的含有环状甘油磷酸酯及其类似物的药物组合物 - Google Patents

用于促进神经细胞分化的含有环状甘油磷酸酯及其类似物的药物组合物 Download PDF

Info

Publication number
CN1348375A
CN1348375A CN00806738A CN00806738A CN1348375A CN 1348375 A CN1348375 A CN 1348375A CN 00806738 A CN00806738 A CN 00806738A CN 00806738 A CN00806738 A CN 00806738A CN 1348375 A CN1348375 A CN 1348375A
Authority
CN
China
Prior art keywords
disease
pharmaceutical composition
nerve
purposes
neural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00806738A
Other languages
English (en)
Chinese (zh)
Inventor
M·辛尼茨基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of CN1348375A publication Critical patent/CN1348375A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
CN00806738A 1999-03-25 2000-03-24 用于促进神经细胞分化的含有环状甘油磷酸酯及其类似物的药物组合物 Pending CN1348375A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL129178 1999-03-25
IL12917899A IL129178A0 (en) 1999-03-25 1999-03-25 Induction of nerve generation

Publications (1)

Publication Number Publication Date
CN1348375A true CN1348375A (zh) 2002-05-08

Family

ID=11072645

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00806738A Pending CN1348375A (zh) 1999-03-25 2000-03-24 用于促进神经细胞分化的含有环状甘油磷酸酯及其类似物的药物组合物

Country Status (16)

Country Link
US (1) US6914056B1 (https=)
EP (1) EP1162959B1 (https=)
JP (1) JP2002540146A (https=)
KR (1) KR20010112364A (https=)
CN (1) CN1348375A (https=)
AT (1) ATE290385T1 (https=)
AU (1) AU768911B2 (https=)
BR (1) BR0009296A (https=)
CA (1) CA2368597A1 (https=)
DE (1) DE60018554T2 (https=)
HK (1) HK1042038A1 (https=)
IL (1) IL129178A0 (https=)
MX (1) MXPA01009650A (https=)
NZ (1) NZ514525A (https=)
RU (1) RU2247557C2 (https=)
WO (1) WO2000057865A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102272080A (zh) * 2009-01-09 2011-12-07 西格马-奥利奇有限公司 β磷酸甘油的合成方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1106180B1 (en) 1999-12-08 2003-11-12 Centre National de la Recherche Scientifique (CNRS) Use of hymenialdisine or derivatives thereof in the manufacture of medicaments
JP4836345B2 (ja) * 2001-04-13 2011-12-14 きみ子 室伏 環状ホスファチジン酸誘導体を含む神経細胞の生存促進剤
JP4815063B2 (ja) * 2001-04-13 2011-11-16 きみ子 室伏 環状ホスファチジン酸を含むグリア細胞の増殖、分化及び／又は生存の促進のための薬剤
IL148665A0 (en) * 2002-03-13 2002-09-12 Yeda Res & Dev Derivatives of 1,3-cyclic propandiol phate and their action as cell stimulants
IL148668A0 (en) * 2002-03-13 2002-09-12 Yeda Res & Dev Derivatives of 1,3-cyclic propandiol phosphate and their action in differentiation therapy
US20050171084A1 (en) * 2002-03-27 2005-08-04 Cairns William J. Methods of treatment with lxr modulators
JP4162927B2 (ja) 2002-06-11 2008-10-08 きみ子 室伏 カルバ環状ホスファチジン酸誘導体
WO2006097924A2 (en) * 2005-03-14 2006-09-21 Yeda Research And Development Company Ltd. Cyclic phosphates as plant growth regulators
JP5695293B2 (ja) * 2006-04-26 2015-04-01 富山化学工業株式会社 アルキルエーテル誘導体またはその塩を含有する神経細胞新生誘導剤および精神障害治療剤
WO2008081580A1 (ja) * 2006-12-28 2008-07-10 Ochanomizu University 環状ホスファチジン酸誘導体を含む鎮痛剤
WO2011065480A1 (ja) * 2009-11-26 2011-06-03 国立大学法人お茶の水女子大学 神経細胞死抑制剤
WO2014115885A1 (ja) 2013-01-28 2014-07-31 国立大学法人お茶の水女子大学 脱髄疾患治療薬
EP2807925A1 (en) * 2013-05-26 2014-12-03 Symrise AG Antimicrobial compositions
AU2016366977A1 (en) * 2015-12-08 2018-07-12 Retrophin, Inc. Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63037A (en) * 1981-06-04 1985-12-31 Israel State Dioxaphosphorinanes,their preparation and pharmaceutical and veterinary compositions containing them
US5565439A (en) * 1992-11-24 1996-10-15 The Procter & Gamble Company Methods of using lysophosphatidic acid for treating hyperproliferative conditions
JPH06228169A (ja) * 1993-02-05 1994-08-16 Sagami Chem Res Center １−ｏ−アシルグリセロール２，３−ホスフェートの製造法
JPH07149772A (ja) * 1993-11-26 1995-06-13 Sagami Chem Res Center タンパク質リン酸化酵素ｃの活性促進剤
JPH07258278A (ja) * 1994-03-18 1995-10-09 Sagami Chem Res Center １−Ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするＤＮＡポリメラーゼαの阻害剤
JPH0925235A (ja) * 1995-07-13 1997-01-28 Sagami Chem Res Center １−ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするがん転移抑制剤
US6150345A (en) * 1998-08-10 2000-11-21 Regents Of The University Of California Methods for promoting survival of myelin producing cells
IL129179A0 (en) * 1999-03-25 2000-02-17 Yeda Res & Dev Cyclic glycerophosphates and analogs thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102272080A (zh) * 2009-01-09 2011-12-07 西格马-奥利奇有限公司 β磷酸甘油的合成方法

Also Published As

Publication number Publication date
AU3451700A (en) 2000-10-16
CA2368597A1 (en) 2000-10-05
IL129178A0 (en) 2000-02-17
EP1162959A2 (en) 2001-12-19
NZ514525A (en) 2003-10-31
RU2247557C2 (ru) 2005-03-10
EP1162959B1 (en) 2005-03-09
BR0009296A (pt) 2001-12-18
AU768911B2 (en) 2004-01-08
WO2000057865A3 (en) 2001-06-28
HK1042038A1 (zh) 2002-08-02
US6914056B1 (en) 2005-07-05
MXPA01009650A (es) 2002-07-02
JP2002540146A (ja) 2002-11-26
WO2000057865A9 (en) 2001-11-15
KR20010112364A (ko) 2001-12-20
DE60018554D1 (de) 2005-04-14
ATE290385T1 (de) 2005-03-15
DE60018554T2 (de) 2006-04-13
WO2000057865A2 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
CN1348375A (zh) 用于促进神经细胞分化的含有环状甘油磷酸酯及其类似物的药物组合物
Longo et al. Action of nicotine and of the" ganglioplegiques centraux" on the electrical activity of the brain
EP1397105B1 (en) Compositions for inhibiting angiogenesis
Osaka et al. Noradrenergic inputs to sleep-related neurons in the preoptic area from the locus coeruleus and the ventrolateral medulla in the rat
Hosford et al. Neural network of structures in which GABAB receptors regulate absence seizures in the lethargic (lh/lh) mouse model
JP5077893B2 (ja) 環状ホスファチジン酸誘導体を含む鎮痛剤
Kofman et al. Intracerebroventricularmyo-inositol antagonizes lithium-induced suppression of rearing behaviour in rats
JPH04230327A (ja) モルヒネおよびその類似体の鎮痛作用に対する耐性の発現を防止する方法
Pan et al. Epileptiform activity and hippocampal damage produced by intrahippocampal injection of guanidinosuccinic acid in rat
Ramírez-Munguía et al. Epilepsy, neurodegeneration, and extracellular glutamate in the hippocampus of awake and anesthetized rats treated with okadaic acid
Millan et al. The involvement of excitatory amino acid receptors within the prepiriform cortex in pilocarpine-induced limbic seizures in rats
US20160354402A1 (en) Compositions
Yount et al. A novel camptothecin analog with enhanced antitumor activity
Ninchoji et al. Effect of pinealectomy on cortically kindled rats
Waddington et al. Characterisation of denervation supersensitivity in the striatonigral gam pathway of the kainic acil-lesioned rat and in huntington's disease
Szentivanyi et al. Studies on the hypothalamic regulation of histamine synthesis history and some current information
CN120168636A (zh) Mcu在治疗成瘾性疾病中的应用
Yamada et al. The response to acoustic stimulation and the changes in brain amine levels after repeated administration of β-phenylethylamine in rats
WO2003075902A2 (en) Derivatives of 1, 3-cyclic propanediol phosphate and their action as cell stimulants
Tsuchiya et al. Intracellular calcium measurement in single brown adipocytes of the rat
Herzog et al. 3.206 First experiences with a decision tool to support appropriate referral for Deep Brain Stimulation in patients with Parkinson's disease
Kovacs et al. 3.207 The impact of the use of Access Therapy Controller on the postoperative outcome
HK1171657A (en) Methods for treating or preventing fatigue
HK1234314A1 (en) Methods for treating or preventing fatigue

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication